1142 GMT - Bayer's legal battles have hit the company's cash flows in recent years, but the group has a path to better cash generation ahead that could aid its debt-reduction efforts, analysts at Bank of America say in a research note. With litigation mostly resolved, the cash-flow outlook for the German group and the growth prospects for its pharmaceutical business could draw investors' attention, the analysts say. Bayer's guidance for 2027 will be a key focus, they add. Bank of America sees potential for Bayer to generate between 3 billion and 5 billion euros in free cash flow over the medium term. Shares rise 2.9%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments